Selective PI3K Alpha Inhibitors via 2-Carboxamide Cycloamino Urea Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for phosphatidylinositol 3-kinases (PI3Ks) lack selectivity for specific subtypes, particularly PI3K alpha, which is a challenge in treating proliferative diseases such as tumors, leukaemias, and myelofibrosis, as they often affect both alpha and other subtypes, leading to non-specific effects.
Innovation Solution
Development of 2-carboxamide cycloamino urea derivatives that selectively inhibit PI3K alpha, offering a high degree of specificity over PI3K beta and gamma subtypes, thereby targeting specific proliferative diseases effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3K inhibitors are used, then PI3K activity is inhibited, but selectivity for specific subtypes (particularly PI3K alpha) is poor
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific structural features at particular positions to target PI3K alpha selectively. The compounds of formula (I) incorporate specific substituents (R1, R2, R3, R4, R5, R6, R7, R8) that create localized interactions with the PI3K alpha binding site, enabling subtype-specific inhibition while maintaining overall molecular stability and activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations in the compounds of formula (I). By adjusting these parameters, the invention optimizes binding affinity and selectivity for PI3K alpha compared to other PI3K subtypes, thereby resolving the contradiction between selectivity and subtype coverage.
2Productivity
If non-specific PI3K inhibitors are used, then broad PI3K pathway inhibition is achieved, but non-specific effects and off-target toxicity increase
Solution Approach 1:
The patent applies segmentation by dividing the PI3K inhibition function into subtype-specific interactions. The compounds of formula (I) are designed with distinct molecular regions that selectively engage with PI3K alpha's unique structural features, allowing effective inhibition of PI3K alpha-mediated pathways while avoiding interactions with other PI3K subtypes and reducing off-target effects.
Solution Approach 2:
The patent uses the compound structure of formula (I) as an intermediary that mediates selective inhibition between the drug molecule and PI3K alpha. The specific molecular architecture acts as a bridge that recognizes and binds to PI3K alpha's unique binding pocket, enabling targeted inhibition without affecting other kinases or pathways.
Data Source
AI summary
The present invention relates to compounds of formula Iand its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.